Strategic Blueprint’s Regeneron Pharmaceuticals REGN Stock Holding History

Strategic Blueprint’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-500	Closed	-$279K	–	1110
2021 Q2	$279K	Hold	500	–	–	0.04%	317
2021 Q1	$237K	Buy	+500	New	+$243K	0.05%	271

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Strategic Blueprint's REGN Position: Q2 2025 in Review

Strategic Blueprint sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 3,788 shares — an estimated $2.4M sold.

Strategic Blueprint first reported a position in REGN in Q2 2020 and held it in 18 quarters. The position peaked at $7.26M in Q4 2021. 1,203 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Strategic Blueprint reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Strategic Blueprint sold 3,788 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $2.4M.
Strategic Blueprint first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 18 quarters.
Strategic Blueprint's Regeneron Pharmaceuticals position peaked at $7.26M in Q4 2021.
1,203 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Strategic Blueprint's 13F filing for Q2 2025, filed 30 Jul 2025.